COVID-19 Inactivated by SPL7013 Nasal Spray - Scripps Research Institute

asx news Sep 14, 2020

Published by Anthony Di Pizio

Did you know ADS Capital can conduct research on stocks of your choice? If you're looking at something and you need a professional opinion, you definitely need to check out what we offer

How It Works

This news by StarPharma Holdings (ASX:SPL) hit the market today. The below is a direct quote from the announcement:

''New data generated at Scripps Research Institute in the US shows that Starpharma's antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19''

Note that SPL7013 is also referred to as astrodrimer sodium. 

This appears to have confirmed the company's assumptions from prior testing:

The potency of SPL7013 was evident when used either before or after the exposure of cells, meaning the nasal spray could be used either before or after exposure to the virus. 

This round of antiviral testing comes after promising announcements from the company in both...

Continue Reading...

Opyl Announces AI Powered COVID-19 Clinical Trial Forecaster

asx news Sep 03, 2020

Published by Anthony Di Pizio

ADS Capital offers general market news and also research on specific stocks. Invest with us to get full access!

Did you know we can research stocks for you? Give it a try!

The contents of the below article do not represent an endorsement of the company by ADS Capital or its associates. 

The News

Melbourne, Australia based Opyl (ASX:OPL) today announced that its Artificial Intelligence (AI) software can make ''probability of success'' predictions on the likelihood of a vaccine or therapy succeeding in clinical trials. They have focused this announcement on COVID-19 but says the software may be used for any clinical trial.

The company claims to have run software tests investigating the 475 registered COVID-19 clinical trials currently underway and:

  1. Has identified the two vaccine candidates most likely to succeed
  2. Determined that at least one antibody therapy has the best probability of success in Phase III trials
  3. Therapies show a much...
Continue Reading...

Subscribe to ADS Capital news

Keep up to date with ADS Capital news articles.